Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-aminobicyclo[2,2,1]heptane-2-carboxylic acid is a **synthetic amino acid derivative** most commonly used as a **selective inhibitor of the large neutral amino acid transporter 1 (LAT1, also called "System L")**[1][2][5]. It competes for the transporter, blocking the cellular uptake of L-type amino acids such as L-leucine and L-dopa, making it a **tool compound** in transporter research and preclinical studies. BCH has shown utility in cancer research by suppressing LAT1-mediated amino acid uptake, leading to **antiproliferative and pro-apoptotic effects** in cancer cells[2][5]. It can also act as an **activator of the mitochondrial enzyme glutamate dehydrogenase (GDH)** in some research contexts[7]. Primary use is as a research tool compound, not a pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-aminobicyclo[2,2,1]heptane-2-carboxylic acid.